Skip to Main Content

Paper Details

TET2-Driven Clonal Hematopoiesis and Response to Canakinumab: An Exploratory Analysis of the CANTOS Randomized Clinical Trial.
JAMA Cardiology
90
2022
C-reactive protein, CHIP, Canankinumab, Clonal hematopoiesis of indeterminate, DNMT3A, IL-1, Patients, TET2, TET2 variants, Tet2, anti-IL-1, atherosclerosis, atherosclerotic cardiovascular disease, genomic DNA, high-sensitivity C-reactive protein, interleukin (IL) 1, mouse, myeloid cells, myocardial infarction, participants, patients, peripheral blood samples
Author NameAffiliation
Catarina D CampbellNovartis Institutes for BioMedical Research
Huilei XuNovartis Institutes for BioMedical Research
Peter LibbyBrigham and Women's Hospital, Harvard Medical School
Paul M RidkerBrigham and Women's Hospital, Harvard Medical School
Paul M RidkerCenter for Cardiovascular Disease Prevention, Brigham and Women's Hospital
  • 1 - 5

Datasets

Release 1.2